Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05341908 · ClinicalTrials.gov registry record
Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
A clinical trial of Joint Infection and Septic Arthritis, sponsored by Olive View-UCLA Education & Research Institute.
- Completed
- Registry status
- 750
- Enrollment target
- 1
- Study location
NCT05341908: Completed study of Joint Infection and Septic Arthritis, sponsored by Olive View-UCLA Education & Research Institute.
NCT05341908 is a study of Joint Infection and Septic Arthritis that has completed, run by Olive View-UCLA Education & Research Institute. The registered enrollment target is 750 participants, above the 294-participant average among 6 other Joint Infection trials with a reported enrollment target (155% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05341908, a study of Joint Infection and Septic Arthritis, has completed, sponsored by Olive View-UCLA Education & Research Institute.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, observational study of patients presenting to the emergency departments at 9 EMERGEncy ID NET sites. The objectives of the proposed study are to: 1. Describe the range and proportion of infectious agents in synovial fluid as detected by standard C\&S and investigational PCR testing, i.e., Biofire® Film Array® Bone and Joint Infection (BJI) Panel, 2. Describe the epidemiology of patients receiving diagnostic arthrocentesis and those diagnosed with septic arthritis in the emergency department (ED), 3. Determine the prevalence of septic arthritis in US ED patients presenting with an atraumatic painful swollen joint, and 4. Determine the clinical (history and physical examination) and laboratory characteristics of septic arthritis. Study coordinators screen the ED log for adult patients presenting with joint pain and whose treating physician ordered an arthrocentesis. After confirming eligibility, study coordinators approach the patient to explain the study, and present the written consent form. If the patient agrees to participate and consent, the study coordinator completes an enrollment data collection using patient and treating physician interview to gather responses. After enrollment, the study coordinator will ensure that approximately 0.3-1.0 mL of leftover synovial fluid is saved and stored in a freezer for shipment to a central laboratory (Truman Medical Center hospital laboratory, Kansas City, MO) for testing. Approximately 30 days after enrollment, study coordinators complete an electronic medical record (EMR) review.
Primary Outcome
We will describe the prevalence of pathogens identified using PCR testing
Conditions Studied
Study Locations (1)
California
- Olive View-UCLA Medical Center - Sylmar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2023-12-31 |
What the finished NCT05341908 record still lists
NCT05341908 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 294-participant average among 6 other Joint Infection trials with a reported enrollment target (155% higher).
The record links to 2 conditions, with Joint Infection appearing as the primary indexed condition, and to 0 interventions.
NCT05341908 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05341908 about?
NCT05341908 is a clinical study titled "Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients". This is a prospective, observational study of patients presenting to the emergency departments at 9 EMERGEncy ID NET sites. The objectives of the proposed study are to: 1. Describe the range and proportion of infectious agents in synovial fluid as detected by standard C\&S and investigational PCR t...
What is the current status of trial NCT05341908?
This trial is currently completed. The enrollment target is 750 participants. The study started on 2021-09-01. Estimated completion is 2023-12-31.
What conditions does trial NCT05341908 study?
This clinical trial studies the following conditions: Joint Infection, Septic Arthritis.
Who is sponsoring clinical trial NCT05341908?
This trial is sponsored by Olive View-UCLA Education & Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05341908 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Joint Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real-component Vs All-cement Articulating Spacers for Periprosthetic Knee Infection
RECRUITING · NA
-
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
RECRUITING · NA
-
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
RECRUITING · NA
-
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
ACTIVE NOT RECRUITING · Phase 2
-
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
COMPLETED · Phase 1
-
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI